MediWound to Participate in Two Upcoming Investor Conferences
YAVNE, Israel, Feb. 05, 2024 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its participation in the upcoming Oppenheimer 34th Annual Life Sciences Conference, taking place virtually on February 13-14, 2024, as well as the upcoming TD Cowen 44th Annual Health Care Conference, taking place in Boston on March 4-6, 2024.
Related news for (MDWD)
- MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
- MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
- MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
- MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care